BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15254592)

  • 1. Hepatitis C virus mutation affects proteasomal epitope processing.
    Seifert U; Liermann H; Racanelli V; Halenius A; Wiese M; Wedemeyer H; Ruppert T; Rispeter K; Henklein P; Sijts A; Hengel H; Kloetzel PM; Rehermann B
    J Clin Invest; 2004 Jul; 114(2):250-9. PubMed ID: 15254592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.
    López-Labrador FX; He XS; Berenguer M; Cheung RC; González-Candelas F; Wright TL; Greenberg HB
    J Med Virol; 2004 Apr; 72(4):575-85. PubMed ID: 14981760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
    Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A
    J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073.
    Fytili P; Dalekos GN; Schlaphoff V; Suneetha PV; Sarrazin C; Zauner W; Zachou K; Berg T; Manns MP; Klade CS; Cornberg M; Wedemeyer H
    Vaccine; 2008 Jul; 26(31):3818-26. PubMed ID: 18582999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between viral fitness and immune escape within the hepatitis C virus protease.
    Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
    Gut; 2006 Feb; 55(2):266-74. PubMed ID: 16105887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
    Engler OB; Schwendener RA; Dai WJ; Wölk B; Pichler W; Moradpour D; Brunner T; Cerny A
    Vaccine; 2004 Nov; 23(1):58-68. PubMed ID: 15519708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection.
    Guglietta S; Garbuglia AR; Pacciani V; Scottà C; Perrone MP; Laurenti L; Spada E; Mele A; Capobianchi MR; Taliani G; Folgori A; Vitelli A; Ruggeri L; Nicosia A; Piccolella E; Del Porto P
    Eur J Immunol; 2005 Sep; 35(9):2627-37. PubMed ID: 16114108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A HLA-A2-restricted-CTL epitope variation at the N-terminal of HCV helicase and the immune response of CTLs].
    Guo HZ; Wang WL; Wang T
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 May; 20(3):325-7. PubMed ID: 15193229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope.
    Brinster C; Muguet S; Lone YC; Boucreux D; Renard N; Fournillier A; Lemonnier F; Inchauspé G
    Hepatology; 2001 Dec; 34(6):1206-17. PubMed ID: 11732011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
    Quiroga JA; Llorente S; Castillo I; Rodríguez-Iñigo E; López-Alcorocho JM; Pardo M; Carreño V
    J Med Virol; 2006 Sep; 78(9):1190-7. PubMed ID: 16847959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells.
    Wedemeyer H; Mizukoshi E; Davis AR; Bennink JR; Rehermann B
    J Virol; 2001 Dec; 75(23):11392-400. PubMed ID: 11689620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C.
    López-Labrador FX; Berenguer M; Sempere A; Prieto M; Sirera R; González-Molina A; Ortiz V; Marty ML; Berenguer J; Gobernado M
    Liver Transpl; 2004 Feb; 10(2):217-27. PubMed ID: 14762859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection.
    Spangenberg HC; Viazov S; Kersting N; Neumann-Haefelin C; McKinney D; Roggendorf M; von Weizsäcker F; Blum HE; Thimme R
    Hepatology; 2005 Oct; 42(4):828-37. PubMed ID: 16175596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.
    Gaudieri S; Rauch A; Park LP; Freitas E; Herrmann S; Jeffrey G; Cheng W; Pfafferott K; Naidoo K; Chapman R; Battegay M; Weber R; Telenti A; Furrer H; James I; Lucas M; Mallal SA
    J Virol; 2006 Nov; 80(22):11094-104. PubMed ID: 17071929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection.
    López-Labrador FX; He XS; Berenguer M; Cheung RC; Wright TL; Greenberg HB
    J Immunol Methods; 2004 Apr; 287(1-2):91-9. PubMed ID: 15099758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution.
    Neumann-Haefelin C; McKiernan S; Ward S; Viazov S; Spangenberg HC; Killinger T; Baumert TF; Nazarova N; Sheridan I; Pybus O; von Weizsäcker F; Roggendorf M; Kelleher D; Klenerman P; Blum HE; Thimme R
    Hepatology; 2006 Mar; 43(3):563-72. PubMed ID: 16496339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I epitope discovery in type 1 diabetes.
    van Endert P; Hassainya Y; Lindo V; Bach JM; Blancou P; Lemonnier F; Mallone R
    Ann N Y Acad Sci; 2006 Oct; 1079():190-7. PubMed ID: 17130554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens.
    Urbani S; Uggeri J; Matsuura Y; Miyamura T; Penna A; Boni C; Ferrari C
    Hepatology; 2001 Jun; 33(6):1533-43. PubMed ID: 11391544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.